Nalmefene Mitigates Opioid‐Induced Nausea and Vomiting in Postoperative Analgesia but Not Resting Pain
Pain Research and Management · 2026-01 · 2026 (1)
DOI: 10.1155/prm/5531157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Research and Management, online erschienen am 25.05.2026. Verfasst von Jiaojiao Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Anesthesiology, Surgery and Pain Management Department, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China, seu.edu.…. Hauptthemen laut MEDLINE: Postoperative Pain, Analgesics, Opioid, Naltrexone, Postoperative Nausea and Vomiting. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Patient‐controlled analgesia (PCA) pumps have emerged as the prevalent modality for managing postoperative pain. Opioids, although widely utilized as analgesic agents in these pumps, are often accompanied by undesirable side effects that can compromise patient comfort and hinder the widespread adoption of PCA therapy.
Methods
We conducted a retrospective study involving 392 patients undergoing lumbar spine surgery who were prescribed PCA pumps for pain relief. Over the initial 1–3 days postsurgery, comprehensive data encompassing resting and activity‐related pain levels, Ramsay sedation scores, activity status, and flatus passage were carefully recorded and analyzed.
Results
Interestingly, patients who received a supplemental dose of nalmefene in their PCA pumps exhibited a notable increase in resting pain intensity on the second postoperative day. However, the incidence of postoperative nausea and vomiting (PONV) was notably reduced (15.5% in the sufentanil + nalmefene group vs 25.5% in the sufentanil group). Notably, no statistically significant variations were discerned between the two groups in Ramsay sedation scores, postoperative activity capabilities, flatus passage, or inflammatory biomarker levels.
Conclusion
The integration of nalmefene into PCA pumps presents a promising strategy for mitigating the occurrence of PONV, albeit with the caveat of potentially compromising opioid‐mediated analgesia, necessitating further research and exploration. The delicate balance between enhancing patient comfort and preserving effective pain control remains a critical area of investigation in the field of postoperative pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anesthesiology, Surgery and Pain Management Department, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China, seu.edu.bd.
ORCID-Profile: Jiaojiao Yang, Baoling Zhang, Lili Qiu, Qiuting Zeng, Jue Xie, Jie Sun
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, J., Zhang, B., Qiu, L., Zeng, Q., Xie, J., & Sun, J. (2026). Nalmefene Mitigates Opioid‐Induced Nausea and Vomiting in Postoperative Analgesia but Not Resting Pain. Pain Research and Management, 2026(1). https://doi.org/10.1155/prm/5531157
Vancouver
Yang J, Zhang B, Qiu L, Zeng Q, Xie J, Sun J. Nalmefene Mitigates Opioid‐Induced Nausea and Vomiting in Postoperative Analgesia but Not Resting Pain. Pain Research and Management. 2026;2026(1). doi:10.1155/prm/5531157
BibTeX
@article{Yang2026,
author = {Yang, Jiaojiao and Zhang, Baoling and Qiu, Lili and Zeng, Qiuting and Xie, Jue and Sun, Jie},
title = {Nalmefene Mitigates Opioid‐Induced Nausea and Vomiting in Postoperative Analgesia but Not Resting Pain},
journal = {Pain Research and Management},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/prm/5531157}
}
EUVIMED